Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

The prevalence of type 2 diabetes (T2D) has reached a pandemic scale. These patients are
at a substantially elevated risk of developing cardiovascular disease, with heart failure (HF) …

The gut-derived incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are secreted after meal ingestion and work in concert to …

The advent of incretin mimetics such as glucagon-like peptide-1 receptor agonists (GLP-1
RAs) has enriched the armamentarium for diabetes management owing to their glycaemic …

Background Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that
stimulates insulin secretion, cellular glucose uptake, and has immune-regulatory functions …

Glucagon-like peptide-1 (GLP-1) has been in focus since the early 1980s as a long looked
for incretin hormone, released from the gastrointestinal tract and with an important effect on …

There is a growing need for treatments for patients who would benefit from further weight
loss following bariatric surgery or weight loss maintenance/long-term disease remission …

OBJECTIVE To explore the efficacy, safety, and tolerability of once-weekly efpeglenatide, a
long-acting glucagon-like peptide 1 receptor agonist (GLP-1 RA), in early type 2 diabetes …

Fatty acid amide hydrolase (FAAH) degrades 2 major classes of bioactive fatty acid amides,
the N-acylethanolamines (NAEs) and N-acyl taurines (NATs), in central and peripheral …

Intestinally derived glucagon-like peptide-1 (GLP-1), encoded by the preproglucagon (Gcg)
gene, is believed to function as an incretin. However, our previous work questioned this …